SEC Form 4 · accession 0001209191-15-005906

TETRAPHASE PHARMACEUTICALS INC · TTPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and Chief Executive · Director

Period of report

Jan 20, 2015

Accepted (ET)

Jan 22, 2015 · 5:53 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001373707

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jan 20, 2015	M	10,000	$7.94	A	60,000	D
Common Stock^F1	Jan 20, 2015	M	849	$0.87	A	60,849	D
Common Stock^F1	Jan 20, 2015	M	22,030	$2.03	A	82,879	D
Common Stock^F1	Jan 20, 2015	M	1,256	$5.80	A	84,135	D
Common Stock^F1,F2	Jan 20, 2015	S	34,135	$36.5892	D	50,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1,F3	$7.94	Jan 20, 2015	M	10,000	D	—	May 14, 2023	Common Stock	10,000	260,000	D
Employee Stock Option (right to buy)^F1,F4	$0.87	Jan 20, 2015	M	849	D	—	Sep 10, 2019	Common Stock	849	109,323	D
Employee Stock Option (right to buy)^F1,F4	$2.03	Jan 20, 2015	M	22,030	D	—	Sep 27, 2020	Common Stock	22,030	57,331	D
Employee Stock Option (right to buy)^F1,F5,F4	$5.80	Jan 20, 2015	M	1,256	D	—	Aug 7, 2018	Common Stock	1,256	25,834	D

F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2014.
F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $35.79 to $38.095 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3Vested as to 25% of the original number of shares granted on 5/15/2014 and further vests as to an additional 6.25% of the original number of shares granted at the end of each successive three-month period thereafter until 5/15/2017.
F4Fully vested.
F5The number of derivative securities beneficially owned following the transaction reported on this Form 4 has been adjusted to reflect the additional 25,834 incentive stock options owned by the reporting person, and previously reported as a separate option owned by the reporting person, in addition to the non-qualified stock options that were previously reported in the Form 4 filed by the reporting person.